RI-refractory Differential Thyroid Carcinoma Prognostic Factors Identified

Share this content:
The identification of prognostic factors for reduced survival in thyroid carcinoma may improve the selection of patients to receive targeted agents.
The identification of prognostic factors for reduced survival in thyroid carcinoma may improve the selection of patients to receive targeted agents.

The identification of prognostic factors for reduced survival in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) may improve the selection of patients to receive targeted agents, a new study published online ahead of print in the journal The Oncologist has shown.1

Because outcomes vary among patients with RR-DTC and the prognostic factors for survival are not well-known, researchers sought to evaluate cancer-specific and overall survival in patients with RR-DTC to identify prognostic factors associated with survival.

For the study, researchers analyzed data from 153 patients with metastatic DTC who were treated between 1990 and 2011 at a single institution in Paris, France. Of those, 91 were radioiodine-refractory.

Results showed that after the diagnosis of radioiodine-refractory, median overall survival was 8.9 years (95% CI, 5.4 - NR) and median cancer-specific survival was 9.6 years (95% CI, 6.01 - NR).

Researchers found that progressive disease despite 131I and time from initial diagnosis of DTC to diagnosis of RR-DTC less than 3 years were independent prognostic factors for poor overall and cancer-specific survival.

RELATED: GEC Testing Does Not Affect Surgical Decision-making Process for Thyroid Nodules

“This study shows a great heterogeneity in terms of prognosis in radioiodine refractory differentiated thyroid carcinoma,” the investigators concluded. “Poorer prognosis is observed in patients with tumor progression or with a diagnosis of radioiodine resistance within 3 years after the initial diagnosis of thyroid cancer.”

“Those findings could lead to improvements in the selection of patients for targeted therapies,” they wrote.

Reference

  1. Wassermann J, Bernier M-O, Spano J-P, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas [published online ahead of print December 16, 2015]. Oncologist. doi: 10.1634/theoncologist.2015-0107.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters